Extracorporeal Shock Wave Therapy for Dysmenorrhea

MTI University50 enrolled

Overview

purpose of this study to investigate the effect of Extracorporeal shock wave therapy on pain and prostaglandin level in patient with primary dysmenorrhea

This randomized controlled trial is to determine the effect of shock wave therapy in the treatment of primary dysmenorrhea. females are randomly assigned into 2 groups: group A SWT treatment plus dietary modification during PD (n=25） GROUP B:dietary modification only (n=25）; Participants in group B will receive dietary modification for three successive months The numerical rating scale (NRS) and prostaglandin blood level will be recorded and evaluated before and after treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Primary Dysmenorrhea

Interventions

shock wave therapyOTHER

Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.

dietary modificationOTHER

Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 25 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. ages ranged between18 - 25 years old. 2. body mass index (BMI) will not exceed 30kg/m2. 3. females will be diagnosed by the physician as primary dysmenorrhea. Exclusion Criteria: 1. Secondary dysmenorrhea . 2. Mental health problem such as depression and anxiety. 3. Irregular periods

Locations (1)

MTI

Cairo, Egypt

Outcomes

Primary Outcomes

numerical rating scale

Numeric rating scale will be 10 cm digital line with 0 (zero) representing feeling no pain and 10 representing feeling the worst pain, was used to assess the severity of the pain before and after treatment for all females in both groups (A\&B). measurement will done twice first one at baseline(will be considered as pre treatment measure) and 2nd on e at 3rd menstrual cycle ( will be considered as post treatment measure)

Time frame: 3 months

Secondary Outcomes

prostaglandin

5cm plasma concentrations of prostaglandin F2α was taken from all females and was analyzed in the Laboratory index to determine the prostaglandin plasma level measurement will done twice before after the treatment program.

Time frame: 3months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.